Studies have shown that active fund managers routinely underperform the S&P500 index*​

Aligos Therapeutics, Inc. (NASDAQ: ALGS)

ALGS Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-11.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%

ALGS Stock Analysis

ALGS PE Ratio:

ALGS PEG Ratio: Not Available

ALGS Forward EPS Growth (12 month): 0.00%

ALGS PS Ratio: 6.8

ALGS PSG Ratio: -1.1

ALGS Forward Revenue Growth (12 month): -6.00%

ALGS Articles

No data was found